Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAB-AXL-ADC · 2 trials · 3 indications
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5
Assess dose limiting toxicity as defined in the protocol
Frequency and severity of AEs and/or SAEs, and changes from baseline in laboratory parameters and vital signs
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| CAB-AXL-ADC (BA3011) | EXPERIMENTAL | CAB-AXL-ADC (BA3011) alone |
| CAB-AXL-ADC (BA3011)+PD-1 inhibitor | EXPERIMENTAL | CAB-AXL-ADC (BA3011) with PD-1 inhibitor |
| BA3011 | EXPERIMENTAL | Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor. |
| Combination Therapy | EXPERIMENTAL | Phase 2: BA3011 in combination with PD-1 inhibitor. |
| Name | Type | Description |
|---|---|---|
| CAB-AXL-ADC | BIOLOGICAL | Conditionally active biologic anti-AXL antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of at least three months. Exclusio...
Top 20 of 84 competitors
CAB-AXL-ADC is an investigational monoclonal antibody being developed for the treatment of Non-Small-Cell Lung Cancer and Undifferentiated Pleomorphic Sarcoma. It is currently in Phase 2 clinical development for these oncology indications.
CAB-AXL-ADC is being developed by BioAtla, Inc., a biopharmaceutical company. BioAtla's stock is traded under the ticker symbol BCAB.
CAB-AXL-ADC is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed for both Non-Small-Cell Lung Cancer and sarcoma indications.
CAB-AXL-ADC has been studied in two completed clinical trials. NCT03425279 was a Phase 1 study in patients with sarcoma, including Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, with 245 participants. NCT04681131 was a Phase 2 study in adults with Non-Small-Cell Lung Cancer, enrolling 85 participants.
CAB-AXL-ADC is the primary name for this investigational drug. No alternative names have been reported for this asset in the available clinical trial information.